



08-01-01

Patent Application  
Attorney Docket No. PC10381A

RECEIVED  
JUL 3 2001  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: HUATAN, ET AL.

APPLICATION NO.: 09/813,340

Examiner: Not Yet Assigned

FILING DATE: March 20, 2001

Group Art Unit: Not Yet Assigned

TITLE: ORAL FORMULATIONS OF  
MEDICAMENTS

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: July 31, 2001

Lorraine B. Ling  
Lorraine B. Ling  
Attorney for Applicant(s)  
Reg. No. 35,251

Pfizer Inc.  
Patent Department, 20th Floor  
235 East 42nd Street  
New York, NY 10017-5755  
(212) 573-2030